{"id":60487,"date":"2024-02-28T06:51:06","date_gmt":"2024-02-28T06:51:06","guid":{"rendered":"https:\/\/medsname.com\/rofaday\/"},"modified":"2026-04-30T10:23:46","modified_gmt":"2026-04-30T10:23:46","slug":"rofaday","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/rofaday\/","title":{"rendered":"Rofaday"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 28px 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 10px 0;font-size:18px;color:#1a1a1a;\">\u26a1 Quick Answer \u2014 What is Rofaday?<\/h3>\n<p><strong>Rofaday<\/strong> obsahuje <strong>roflumilast 500 mcg<\/strong>, , <strong>oral selective phosphodiesterase-4 (PDE4) inhibitor<\/strong> taken once daily for <strong>severe chronic obstructive pulmonary disease (COPD) with chronic bronchitis phenotype and frequent exacerbations<\/strong>. Roflumilast is anti-inflammatory rather than bronchodilator \u2014 it suppresses neutrophil and macrophage activation in airways, reducing exacerbation frequency by ~17% in landmark trials (M2-124, M2-125, REACT). It is added on top of optimal LAMA + LABA (\u00b1 ICS) in patients with severe disease. Manufactured by <strong>Cipla<\/strong>.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<div style=\"background:#f4f8fb;border:1px solid #e0e0e0;padding:12px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;text-align:center;\">\n<strong>\ud83d\udd12 \u0160ifrovan\u00fd n\u00e1kup<\/strong> \u00b7 <strong>\ud83d\udcb3 Ov\u011b\u0159en\u00fd procesor<\/strong> \u00b7 <strong>\ud83d\ude9a Doprava po cel\u00e9m sv\u011bt\u011b<\/strong> \u00b7 <strong>\u2b50 4,9\/5 od 1 400+ z\u00e1kazn\u00edk\u016f<\/strong>\n<\/div>\n<h2>What Is Rofaday?<\/h2>\n<p>Rofaday is an oral PDE4 inhibitor for severe COPD. Roflumilast is the only PDE4 inhibitor licensed for COPD \u2014 sold internationally as Daxas (AstraZeneca) and Daliresp. It is a niche but well-evidenced add-on for the chronic bronchitis phenotype.<\/p>\n<h2>How Does Rofaday Work?<\/h2>\n<p>Phosphodiesterase-4 (PDE4) is the dominant cyclic AMP-degrading enzyme in inflammatory cells (neutrophils, macrophages, eosinophils, T-cells). Inhibiting PDE4 raises cyclic AMP in these cells, suppressing:<\/p>\n<ul>\n<li>Neutrophil chemotaxis and degranulation in airways<\/li>\n<li>Macrophage cytokine release (TNF-\u03b1, IL-8)<\/li>\n<li>Airway smooth-muscle proliferation and fibroblast activation<\/li>\n<li>Mucus hypersecretion and goblet-cell hyperplasia<\/li>\n<\/ul>\n<p>The clinical result is a 15\u201317% reduction in COPD exacerbation rate when added to optimal inhaled therapy.<\/p>\n<h2>Pou\u017eit\u00ed a indikace<\/h2>\n<ul>\n<li><strong>Severe COPD (FEV1 &lt;50% predicted) with chronic bronchitis<\/strong> and a history of exacerbations, on top of optimal LAMA + LABA (\u00b1 ICS)<\/li>\n<li><strong>Frequent exacerbator phenotype<\/strong> with persistent productive cough<\/li>\n<\/ul>\n<h2>Rofaday Dosage<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Pacient<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">D\u00e1vka<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Frekvence<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Adults \u2014 start<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><strong>250 mcg<\/strong> for first 4 weeks<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Jednou denn\u011b<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Dosp\u011bl\u00ed \u2014 udr\u017eovac\u00ed d\u00e1vka<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><strong>500 mcg<\/strong><\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Once daily, with or without food<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Porucha funkce jater<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid (Child-Pugh B\/C)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Side Effects of Rofaday<\/h2>\n<ul>\n<li><strong>\u00dabytek hmotnosti<\/strong> (averages 2\u20133 kg in trials \u2014 monitor; reverse if &gt;5%)<\/li>\n<li>Diarrhoea, nausea (commonest reason for discontinuation; usually settles after first 2\u20134 weeks)<\/li>\n<li>Bolest hlavy<\/li>\n<li>Insomnia, anxiety<\/li>\n<li>Dyspepsia, abdominal pain<\/li>\n<li>Mood changes \u2014 depression, anxiety; rarely suicidal ideation (warning)<\/li>\n<\/ul>\n<p><strong>Z\u00e1va\u017en\u00e9 \u2014 p\u0159esta\u0148te u\u017e\u00edvat a vyhledejte pomoc:<\/strong><\/p>\n<ul>\n<li>Severe weight loss (&gt;5% body weight)<\/li>\n<li>New or worsening depression, suicidal thoughts<\/li>\n<li>Severe persistent diarrhoea<\/li>\n<li>Z\u00e1va\u017en\u00e1 alergick\u00e1 reakce<\/li>\n<\/ul>\n<h2>Varov\u00e1n\u00ed a opat\u0159en\u00ed<\/h2>\n<ul>\n<li><strong>Mood and behaviour:<\/strong> screen for depression before starting; warn patients\/families to report new mood symptoms.<\/li>\n<li><strong>Weight loss:<\/strong> baseline and 3-monthly weight monitoring; if loss exceeds 5%, review or stop.<\/li>\n<li><strong>Porucha funkce jater:<\/strong> avoid in Child-Pugh B and C.<\/li>\n<li><strong>4-week dose titration<\/strong> (250 mcg) reduces GI side effects and diarrhoea \u2014 most patients can then tolerate 500 mcg.<\/li>\n<li><strong>Not a bronchodilator<\/strong> \u2014 does not replace LAMA, LABA, or ICS.<\/li>\n<li><strong>T\u011bhotenstv\u00ed a kojen\u00ed:<\/strong> kontraindikov\u00e1no.<\/li>\n<li><strong>Interakce s l\u00e9ky:<\/strong> CYP3A4 inducers (rifampicin) reduce levels \u2014 avoid. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) raise levels \u2014 caution.<\/li>\n<\/ul>\n<h2>Kontraindikace<\/h2>\n<ul>\n<li>Hypersensitivity to roflumilast<\/li>\n<li>Moderate-to-severe hepatic impairment (Child-Pugh B\/C)<\/li>\n<li>T\u011bhotenstv\u00ed<\/li>\n<\/ul>\n<h2>Interakce s l\u00e9\u010divy<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Interaguj\u00edc\u00ed l\u00e9k<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">\u00da\u010dinek<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Co d\u011blat<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">CYP3A4 inducers (rifampicin, phenobarbital, phenytoin, carbamazepine)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce roflumilast levels by 50%<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Vyhnout se<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, enoxacin)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Raise roflumilast levels \u2014 increase side effect risk<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Caution; consider lower dose<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Oral contraceptives containing gestodene<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Modest increase in roflumilast levels<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">No dose adjustment usually needed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Skladov\u00e1n\u00ed<\/h2>\n<ul>\n<li>Skladujte p\u0159i teplot\u011b do <strong>25\u00b0C<\/strong> na chladn\u00e9m, such\u00e9m m\u00edst\u011b, chr\u00e1n\u011bn\u00e9m p\u0159ed p\u0159\u00edm\u00fdm slune\u010dn\u00edm z\u00e1\u0159en\u00edm.<\/li>\n<li>Ponechte v p\u016fvodn\u00edm obalu a\u017e do pou\u017eit\u00ed, aby byl chr\u00e1n\u011bn p\u0159ed vlhkost\u00ed a sv\u011btlem.<\/li>\n<li>Nepou\u017e\u00edvejte po uplynut\u00ed data expirace uveden\u00e9ho na blistru.<\/li>\n<li>Uchov\u00e1vejte mimo dosah d\u011bt\u00ed.<\/li>\n<\/ul>\n<h2>Souvisej\u00edc\u00ed alternativy na MedsBase<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/asthalin-inhaler\/\"><strong>Asthalin Inhaler \u2014 salbutamol \u00falevov\u00fd inhal\u00e1tor<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/budecort-inhaler\/\"><strong>Budecort Inhaler \u2014 budesonid preventivn\u00ed ICS inhal\u00e1tor<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/foracort-inhaler\/\"><strong>Foracort Inhaler \u2014 budesonid + formoterol ICS-LABA inhal\u00e1tor<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/tiova-inhaler\/\"><strong>Tiova Inhaler \u2014 tiotropium LAMA pro CHOPN<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/montair\/\"><strong>Montair \u2014 montelukast LTRA tablety<\/strong><\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3>When is Rofaday added?<\/h3>\n<p>For severe COPD (FEV1 <50% predicted) with chronic bronchitis phenotype and a history of frequent exacerbations on top of optimal LAMA + LABA (\u00b1 ICS). Not for mild COPD or asthma.<\/p>\n<h3>Why must I start at 250 mcg?<\/h3>\n<p>A 4-week titration at 250 mcg dramatically reduces GI side effects (diarrhoea, nausea) \u2014 most patients can then move to the maintenance 500 mcg without intolerance.<\/p>\n<h3>How much does Rofaday reduce exacerbations?<\/h3>\n<p>About 15\u201317% reduction in moderate-to-severe COPD exacerbations in landmark trials (M2-124, M2-125, REACT). Most benefit seen in the chronic bronchitis with frequent exacerbator phenotype.<\/p>\n<h3>Will Rofaday make me lose weight?<\/h3>\n<p>Yes \u2014 average 2\u20133 kg in trials. Monitor weight at baseline and every 3 months. If loss exceeds 5%, review indication or stop.<\/p>\n<h3>A co zm\u011bny n\u00e1lady?<\/h3>\n<p>Rare but reported. Screen for depression at baseline; counsel patient and family to report new mood symptoms, anxiety, or suicidal thoughts. Stop and review.<\/p>\n<h3>Is Rofaday a bronchodilator?<\/h3>\n<p>No \u2014 it is anti-inflammatory only. Continue your LAMA, LABA, and (where indicated) ICS inhalers.<\/p>\n<h3>Can I take Rofaday during pregnancy?<\/h3>\n<p>Kontraindikov\u00e1no.<\/p>\n<h3>How does Rofaday compare to triple therapy?<\/h3>\n<p>Triple inhaler (Triohale) and Rofaday tackle COPD exacerbations through different mechanisms (bronchodilation + inflammation suppression vs PDE4-mediated anti-inflammation). Some patients benefit from both.<\/p>\n<h3>What are the most important drug interactions?<\/h3>\n<p>Rifampicin (and other CYP3A4 inducers) reduce Rofaday levels by half \u2014 avoid. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) raise levels \u2014 caution.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:24px 0;border-radius:4px;font-size:13px;\"><strong>Zdravotn\u00ed upozorn\u011bn\u00ed:<\/strong> Tato str\u00e1nka je vzd\u011bl\u00e1vac\u00ed a nenahrazuje odbornou l\u00e9ka\u0159skou pomoc. P\u0159ed zah\u00e1jen\u00edm, ukon\u010den\u00edm nebo zm\u011bnou jak\u00e9hokoli inhal\u00e1toru nebo respira\u010dn\u00edho l\u00e9ku se v\u017edy pora\u010fte s kvalifikovan\u00fdm zdravotnick\u00fdm pracovn\u00edkem, zejm\u00e9na pokud m\u00e1te jin\u00e9 zdravotn\u00ed pot\u00ed\u017ee, u\u017e\u00edv\u00e1te jin\u00e9 l\u00e9ky, jste t\u011bhotn\u00e1 nebo koj\u00edte, nebo je v\u00e1m v\u00edce ne\u017e 65 let.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Souvisej\u00edc\u00ed alternativy<\/h3>\n<p>Dal\u0161\u00ed produkty v <strong>Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/glycomet-gp\/\">Glycomet-GP<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/loratin\/\">Loratin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/lasix\/\">Lasix<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/decdan\/\">Decdan<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/hydrocl\/\">Hydrocl<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Reduces lung inflammation<br \/>\n\u2705 Zlep\u0161uje funkci plic<br \/>\n\u2705 Treats chronic bronchitis<br \/>\n\u2705 Decreases COPD exacerbations<br \/>\n\u2705 Enhances breathing capacity<\/p>\n<p>Rofaday contains Roflumilast.<\/p>","protected":false},"featured_media":60488,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3681,3141,3223],"product_tag":[4868,4869],"class_list":{"0":"post-60487","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-asthma-copd-treatment","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_tag-rofaday","10":"product_tag-roflumilast","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/60487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=60487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/60488"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=60487"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=60487"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=60487"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=60487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}